期刊
LEUKEMIA
卷 25, 期 6, 页码 906-908出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2011.29
关键词
myeloma; extramedullary; pomalidomide
资金
- Celgene
- Novartis
- Millennium
- Bayer
- Genzyme
We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years following diagnosis of MM was 3%. The response of EMD to pomalidomide plus low-dose dexamethasone included two complete and two partial responses among the 13 patients (response rate, 31%). Overall survival measured from trial entry was significantly shorter for patients with treatment-emergent EMD compared with those who did not have EMD, (median 16 months versus not reached, P = 0.002). Leukemia (2011) 25, 906-908; doi:10.1038/leu.2011.29; published online 25 February 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据